CONSULTECH TECHNOLOGIEBERATUNG GMBH

Their core work

Consultech is a Berlin-based technology consultancy (SME) that supports health-research consortia with project coordination, management, and commercialization services. Their substantive work concentrates on clinical biomarker validation and pain research, acting as the administrative and strategic backbone for multi-country trials involving hospitals, universities, and pharma partners. They are not a lab or a clinic — they are the organizational layer that turns scientific consortia into delivered projects. Their value to partners is operational: grant architecture, consortium management, reporting, and exploitation planning.

What they specialise in

How they've shifted over time

In their first H2020 engagement (GLIOMARK, 2015-2021) Consultech led a focused SME-instrument effort on neuro-oncology diagnostic validation. From 2018 they moved into the much larger pain-research domain via IMI-PainCare, broadening from single-disease biomarker validation toward clinical phenotyping, PROMs, and patient stratification. The trajectory goes from coordinating a compact diagnostics SME project to partnering inside a massive Innovative Medicines Initiative consortium.

They are moving from leading small SME diagnostic projects toward serving as a management partner inside large IMI-style public-private pharma consortia — useful for anyone building a big, multi-country health trial.

How they like to work

Consultech plays two complementary roles: coordinator of a small SME-led consortium (GLIOMARK) and specialist partner inside a very large IMI consortium (IMI-PainCare). Despite only two projects, they have touched 41 partners across 15 countries, meaning their collaboration footprint is disproportionately wide for their size. They work comfortably in both tight SME teams and sprawling pharma-academic networks, which is unusual for a small consultancy.

A wide European network: 41 unique partners across 15 countries from just two projects, driven by their seat in the IMI-PainCare consortium which pulls together pharma, academic hospitals, and SMEs across the EU.

What sets them apart

Most German technology consultancies stay on the sidelines as junior partners — Consultech has actually coordinated a multi-million-euro SME-2 health project and earned a seat at the IMI-PainCare table. For a scientific partner, this means they understand both the small-project SME-instrument mechanics and the heavyweight IMI governance model. For a business, they are a small, accessible Berlin SME that has still touched 41 European partners and can open doors in clinical research networks.

Highlights from their portfolio

• GLIOMARK
  They coordinated this EUR 3.3M SME-2 project on validating blood-brain-barrier permeability as a glioma biomarker — an unusually large lead role for a consultancy of this size.
• IMI-PainCare
  Participation in a flagship Innovative Medicines Initiative consortium on acute and chronic pain, giving them exposure to endometriosis, bladder pain syndrome, PROMs, and deep phenotyping work alongside major pharma companies.